TY  - JOUR
AU  - Escudero-Sanchez, Rosa
AU  - Ruiz-Ruizgomez, Maria
AU  - Fernandez-Fradejas, Jorge
AU  - Garcia-Fernandez, Sergio
AU  - Olmedo-Samperio, Maria
AU  - Cano-Yuste, Angela
AU  - Valencia-Alijo, Angela
AU  - Diaz-Pollan, Beatriz
AU  - Rodriguez-Hernandez, Maria Jesus
AU  - Merino-De-Lucas, Esperanza
AU  - Martin-Segarra, Oriol
AU  - Saez-Bejar, Carmen
AU  - Armiñanzas-Castillo, Carlos
AU  - Gutierrez-Gutierrez, Belen
AU  - Rodriguez-Pardo, Dolors
AU  - Ramos-Martinez, Antonio
AU  - De-La-Torre-Cisneros, Julian
AU  - Lopez-Medrano, Francisco
AU  - Cobo-Reinoso, Javier
PY  - 2020
DO  - 10.3390/jcm10010002
SN  - 2077-0383
UR  - http://hdl.handle.net/10668/16868
T2  - Journal of clinical medicine
AB  - Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was...
LA  - en
PB  - MDPI
KW  - C. difficile infection
KW  - Clostridioides difficile
KW  - Clostridium difficile
KW  - Bezlotoxumab
KW  - Recurrence
KW  - Humans
KW  - Bezlotoxumab
KW  - Spain
KW  - Cohort studies
KW  - Follow-up studies
KW  - Clostridium infections
KW  - Risk factors
KW  - Prescriptions
TI  - Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection.
TY  - research article
VL  - 10
ER  -